# A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Source: https://onco.cc/trials/nct06776952/  
OnCo record `nct06776952` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tucidinostat (chidamide) and XNW5004 in peripheral T-cell lymphomas, run by Evopoint Biosciences Inc., now recruiting.

## Summary

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma is a phase 3 interventional study registered as NCT06776952 by Evopoint Biosciences Inc., with 120 participants planned, started 2025-04-10 and due to reach its primary completion in 2028-01. Interventions recorded: XNW5004 ; Chidamide placebo and XNW5004 placebo; Chidamide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06776952
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
- Sponsor: Evopoint Biosciences Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06776952: https://clinicaltrials.gov/study/NCT06776952

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/), [XNW5004](https://onco.cc/drugs/xnw5004/)
- companies: [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06776952.json